- Home
- KLRS vs WIMI Comparison
KLRS vs WIMI Comparison
Compare KLRS & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- WIMI
- Stock Information
- Founded
- KLRS 2019
- WIMI 2015
- Country
- KLRS United States
- WIMI China
- Employees
- KLRS N/A
- WIMI N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- WIMI Computer Software: Prepackaged Software
- Sector
- KLRS Health Care
- WIMI Technology
- Exchange
- KLRS Nasdaq
- WIMI Nasdaq
- Market Cap
- KLRS 46.0M
- WIMI 51.6M
- IPO Year
- KLRS N/A
- WIMI 2020
- Fundamental
- Price
- KLRS $4.97
- WIMI $3.78
- Analyst Decision
- KLRS Strong Buy
- WIMI
- Analyst Count
- KLRS 2
- WIMI 0
- Target Price
- KLRS $23.00
- WIMI N/A
- AVG Volume (30 Days)
- KLRS 175.7K
- WIMI 243.3K
- Earning Date
- KLRS 11-15-2025
- WIMI 01-01-0001
- Dividend Yield
- KLRS N/A
- WIMI N/A
- EPS Growth
- KLRS N/A
- WIMI N/A
- EPS
- KLRS N/A
- WIMI 1.43
- Revenue
- KLRS N/A
- WIMI $61,329,146.00
- Revenue This Year
- KLRS N/A
- WIMI N/A
- Revenue Next Year
- KLRS N/A
- WIMI N/A
- P/E Ratio
- KLRS N/A
- WIMI $2.56
- Revenue Growth
- KLRS N/A
- WIMI N/A
- 52 Week Low
- KLRS $2.14
- WIMI $2.24
- 52 Week High
- KLRS $24.15
- WIMI $29.20
- Technical
- Relative Strength Index (RSI)
- KLRS 49.92
- WIMI 38.91
- Support Level
- KLRS $4.70
- WIMI $3.64
- Resistance Level
- KLRS $5.30
- WIMI $4.16
- Average True Range (ATR)
- KLRS 0.41
- WIMI 0.23
- MACD
- KLRS -0.06
- WIMI -0.04
- Stochastic Oscillator
- KLRS 67.48
- WIMI 11.34
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.